home
investors
newsroom
licensing
contact us
United States
Canada
MSD Worldwide
About Us
Our Values
Be well
Leadership
How We Operate
Views and Positions
Our History
Featured Stories
Corporate Responsibility
Research
Pipeline
Discovery & Development
Products
Vaccines
Prescription Products & Prescribing Information
Consumer Products
Animal Health
Careers
United States
Canada
MSD Worldwide
INVESTED IN
YOUR FUTURE
INVESTORS
Financials
Form 10-K, Proxy Statements and Annual Reports
SEC Filings & Certifications
Earnings Releases
Quarterly Financials
Stock Information
Stock Chart
Historical Price Lookup
Stock Splits
Cash Dividend History
Investment Calculator
Partnerships
Events & Presentations
Stockholder Services
Information Request
Forward-Looking Statement
Contact Us
LATEST NEWS
more news
May 22, 2012
Merck Announces Third-Quarter 2012 Dividend
May 21, 2012
FDA Approves New Labeling for ISENTRESS
®
(raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1
May 16, 2012
Merck to Present at Bank of America Merrill Lynch 2012 Healthcare Conference
Print
Share
Text Size
Access
Related Information
Corporate Responsibility Report
Product Pipeline
Learn more
Vaccine Supply
Merck Vaccine Supply Status Update
Podcast